Vera Therapeutics (VERA) Financials

$21.29 +0.05 (+0.24%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$21.30 +0.02 (+0.07%)

As of 04/17/2025 06:00 PM Eastern

Annual Income Statements for Vera Therapeutics

This table shows Vera Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-53	-33	-89	-96	-152
Consolidated Net Income / (Loss)	-53	-33	-89	-96	-152
Net Income / (Loss) Continuing Operations	-53	-33	-89	-96	-152
Total Pre-Tax Income	-53	-33	-89	-96	-152
Total Operating Income	-52	-34	-91	-102	-167
Total Gross Profit	0.00	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	52	34	91	102	167
Selling, General & Admin Expense	4.04	12	22	24	41
Research & Development Expense	45	22	69	78	126
Total Other Income / (Expense), net	-1.17	1.79	1.85	6.02	15
Interest Expense	0.17	0.02	0.99	3.79	7.63
Interest & Investment Income	0.01	0.02	1.75	7.98	21
Other Income / (Expense), net	-1.01	1.80	1.09	1.83	1.94
Income Tax Expense	-0.00	0.00	0.00	0.00	0.00
Basic Earnings per Share	($166.93)	($2.43)	($3.35)	($2.25)	($2.75)
Weighted Average Basic Shares Outstanding	319.96K	13.44M	26.57M	42.71M	55.33M
Diluted Earnings per Share	($166.93)	($2.43)	($3.35)	($2.25)	($2.75)
Weighted Average Diluted Shares Outstanding	319.96K	13.44M	26.57M	42.71M	55.33M
Weighted Average Basic & Diluted Shares Outstanding	319.96K	13.44M	44.26M	54.45M	0.00

This table shows Vera Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-25	-32	-30	-20	-20	-26	-28	-34	-47	-43
Consolidated Net Income / (Loss)	-25	-32	-30	-20	-20	-26	-28	-34	-47	-43
Net Income / (Loss) Continuing Operations	-25	-32	-30	-20	-20	-26	-28	-34	-47	-43
Total Pre-Tax Income	-25	-32	-30	-20	-20	-26	-28	-34	-47	-43
Total Operating Income	-25	-34	-31	-22	-22	-27	-31	-37	-50	-49
Total Operating Expenses	25	34	31	22	22	27	31	37	50	49
Selling, General & Admin Expense	5.59	6.91	6.15	5.74	5.66	6.24	7.91	8.03	9.49	16
Research & Development Expense	20	27	25	16	16	21	23	29	40	33
Total Other Income / (Expense), net	0.57	1.14	1.19	1.81	1.65	1.37	2.73	3.64	3.17	5.49
Interest Expense	0.15	0.60	0.87	0.91	0.94	1.06	1.91	1.91	1.94	1.87
Interest & Investment Income	0.57	0.89	1.62	2.24	2.16	1.96	4.19	5.10	4.76	6.66
Other Income / (Expense), net	0.15	0.85	0.44	0.48	0.44	0.47	0.45	0.44	0.34	0.70
Basic Earnings per Share	($0.91)	($1.18)	($0.80)	($0.46)	($0.45)	($0.54)	($0.56)	($0.62)	($0.85)	($0.72)
Weighted Average Basic Shares Outstanding	27.22M	26.57M	37.67M	44.27M	44.36M	42.71M	50.97M	54.73M	54.90M	55.33M
Diluted Earnings per Share	($0.91)	($1.18)	($0.80)	($0.46)	($0.45)	($0.54)	($0.56)	($0.62)	($0.85)	($0.72)
Weighted Average Diluted Shares Outstanding	27.22M	26.57M	37.67M	44.27M	44.36M	42.71M	50.97M	54.73M	54.90M	55.33M
Weighted Average Basic & Diluted Shares Outstanding	27.66M	44.26M	44.26M	44.32M	44.43M	54.45M	54.70M	54.83M	63.32M	0.00

This table details how cash moves in and out of Vera Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	19	26	-36	1.93	47
Net Cash From Operating Activities	-35	-24	-68	-92	-135
Net Cash From Continuing Operating Activities	-66	-24	-68	-92	-135
Net Income / (Loss) Continuing Operations	-53	-33	-89	-96	-152
Consolidated Net Income / (Loss)	-53	-33	-89	-96	-152
Depreciation Expense	0.25	0.18	-0.85	0.02	0.11
Amortization Expense	-	-	-	-4.11	-8.16
Non-Cash Adjustments To Reconcile Net Income	18	1.21	13	14	23
Changes in Operating Assets and Liabilities, net	0.12	7.51	9.35	-5.82	2.66
Net Cash From Investing Activities	-0.04	-4.20	-71	-39	-425
Net Cash From Continuing Investing Activities	-0.04	-4.20	-71	-39	-425
Purchase of Property, Plant & Equipment	-0.10	-5.00	-0.06	-0.06	-0.97
Purchase of Investments	-	0.00	-148	-225	-703
Sale and/or Maturity of Investments	-	0.00	78	186	279
Net Cash From Financing Activities	85	54	102	134	607
Net Cash From Continuing Financing Activities	86	54	102	134	607
Repayment of Debt	-0.02	4.92	-	25	0.00
Repurchase of Common Equity	0.00	-2.77	-	0.00	-0.01
Issuance of Common Equity	0.00	52	88	116	646
Other Financing Activities, net	0.10	0.00	14	-7.26	-39
Cash Interest Paid	0.03	0.02	0.90	3.35	6.65

This table details how cash moves in and out of Vera Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-20	13	94	-104	-6.45	18	23	-44	2.17	65
Net Cash From Operating Activities	-18	-21	-26	-18	-23	-25	-34	-25	-37	-39
Net Cash From Continuing Operating Activities	-18	-21	-26	-18	-23	-25	-34	-25	-37	-39
Net Income / (Loss) Continuing Operations	-25	-32	-30	-20	-20	-26	-28	-34	-47	-43
Consolidated Net Income / (Loss)	-25	-32	-30	-20	-20	-26	-28	-34	-47	-43
Depreciation Expense	-0.15	-0.60	-0.51	0.52	0.01	0.00	-1.47	1.50	0.02	0.06
Amortization Expense	-	-	-	-	-3.09	-1.17	-	-	-6.70	-1.85
Non-Cash Adjustments To Reconcile Net Income	6.23	2.65	2.57	2.29	5.11	3.75	4.00	1.54	11	6.77
Changes in Operating Assets and Liabilities, net	0.18	9.23	1.72	-0.57	-4.90	-2.08	-7.98	5.51	5.86	-0.73
Net Cash From Investing Activities	-2.44	13	12	-86	16	19	-219	-23	38	-221
Net Cash From Continuing Investing Activities	-2.44	13	12	-86	16	19	-219	-23	38	-221
Purchase of Property, Plant & Equipment	-0.04	-	-	-	-	-0.06	-	-	-0.24	-0.65
Purchase of Investments	-40	-11	-34	-109	-29	-53	-255	-81	-73	-294
Sale and/or Maturity of Investments	38	24	46	22	45	72	36	59	112	73
Net Cash From Financing Activities	0.91	21	108	0.43	0.30	25	277	3.44	0.74	326
Net Cash From Continuing Financing Activities	0.91	21	108	0.43	0.30	25	277	3.44	0.74	326
Issuance of Common Equity	0.98	0.83	115	0.43	0.30	0.09	294	3.44	0.75	347
Other Financing Activities, net	-0.07	20	-7.26	-	-	-	-18	-	-	-21
Cash Interest Paid	0.12	0.56	3.25	-1.62	0.86	0.85	1.52	1.73	1.74	1.66

This table presents Vera Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Total Assets	55	84	131	176	656
Total Current Assets	54	83	126	172	651
Cash & Equivalents	54	80	43	46	93
Short-Term Investments	-	0.00	71	115	548
Prepaid Expenses	0.56	2.86	11	11	10
Plant, Property, & Equipment, net	0.00	0.00	0.05	0.09	0.96
Total Noncurrent Assets	0.29	1.21	5.69	3.43	3.50
Other Noncurrent Operating Assets	0.29	0.34	5.63	3.43	3.50
Total Liabilities & Shareholders' Equity	55	84	131	176	656
Total Liabilities	4.33	14	55	74	79
Total Current Liabilities	2.41	7.69	26	22	25
Accounts Payable	0.91	1.39	12	11	7.67
Accrued Expenses	0.54	5.93	11	8.75	16
Other Current Liabilities	0.96	0.38	2.65	2.44	1.48
Total Noncurrent Liabilities	1.92	6.47	29	52	53
Long-Term Debt	-	4.92	25	50	51
Other Noncurrent Operating Liabilities	0.29	0.29	4.12	1.68	2.47
Total Equity & Noncontrolling Interests	-89	70	77	102	577
Total Preferred & Common Equity	-89	70	77	102	577
Preferred Stock	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-89	70	77	102	577
Common Stock	2.10	194	290	410	1,038
Retained Earnings	-91	-124	-213	-309	-461
Accumulated Other Comprehensive Income / (Loss)	-	0.00	-0.22	0.25	0.39

This table presents Vera Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	131	210	195	176	419	397	369
Total Current Assets	125	204	191	172	416	395	364
Cash & Equivalents	30	137	34	27	69	25	27
Short-Term Investments	84	60	147	132	335	359	326
Prepaid Expenses	11	7.30	9.59	12	13	10	11
Plant, Property, & Equipment, net	0.06	0.05	0.04	0.03	0.08	0.16	0.37
Total Noncurrent Assets	6.33	5.11	4.52	3.96	2.91	2.39	4.06
Other Noncurrent Operating Assets	6.21	5.05	4.50	3.95	2.91	2.39	4.06
Total Liabilities & Shareholders' Equity	131	210	195	176	419	397	369
Total Liabilities	26	52	55	52	66	69	80
Total Current Liabilities	16	24	27	25	15	18	26
Accounts Payable	7.01	5.33	13	12	5.21	4.66	4.60
Accrued Expenses	6.22	16	11	9.80	7.06	12	20
Other Current Liabilities	2.69	2.60	2.56	2.52	2.28	2.12	1.87
Total Noncurrent Liabilities	9.73	28	28	27	51	51	53
Long-Term Debt	4.97	25	25	25	50	50	50
Other Noncurrent Operating Liabilities	4.77	3.48	2.86	2.25	1.21	0.74	2.57
Total Equity & Noncontrolling Interests	106	158	141	124	354	328	289
Total Preferred & Common Equity	106	158	141	124	354	328	289
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	106	158	141	124	354	328	289
Common Stock	287	401	404	407	691	700	706
Retained Earnings	-181	-243	-263	-283	-337	-371	-418
Accumulated Other Comprehensive Income / (Loss)	-0.28	-0.00	-0.14	-0.08	-0.17	-0.45	1.04

This table displays calculated financial ratios and metrics derived from Vera Therapeutics' official financial filings.

Metric	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	0.00%	38.82%	-179.58%	-15.01%	-66.20%
EBIT Growth	0.00%	38.78%	-175.47%	-11.55%	-64.93%
NOPAT Growth	0.00%	34.15%	-164.24%	-12.22%	-63.87%
Net Income Growth	0.00%	38.95%	-173.10%	-7.79%	-58.50%
EPS Growth	0.00%	98.54%	-37.86%	32.84%	-22.22%
Operating Cash Flow Growth	0.00%	31.89%	-185.12%	-36.37%	-46.10%
Free Cash Flow Firm Growth	0.00%	0.00%	-163.17%	-32.79%	-50.39%
Invested Capital Growth	0.00%	-73.36%	-115.62%	29.55%	-42.12%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	45.16%	-22.30%	2.50%	-17.38%
EBIT Q/Q Growth	0.00%	44.39%	-21.51%	5.81%	-15.08%
NOPAT Q/Q Growth	0.00%	43.02%	-23.00%	6.04%	-15.06%
Net Income Q/Q Growth	0.00%	44.39%	-21.22%	6.60%	-13.22%
EPS Q/Q Growth	0.00%	98.35%	-140.26%	22.15%	-7.00%
Operating Cash Flow Q/Q Growth	0.00%	46.91%	-27.85%	-4.51%	-11.64%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-14.00%	-9.61%	-14.17%
Invested Capital Q/Q Growth	0.00%	-229.65%	-236.78%	18.29%	5.59%
Profitability Metrics	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	100.30%	100.02%	99.16%	95.81%	92.08%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-106.34%	-54.43%	-121.58%	-107.50%	-44.83%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	189.16%	8.97%	-121.55%	-107.45%	-44.82%
Return on Equity Simple (ROE_SIMPLE)	59.78%	-46.86%	-115.80%	-94.40%	-26.36%
Net Operating Profit after Tax (NOPAT)	-37	-24	-64	-71	-117
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-31.37%	-13.19%	-30.72%	-24.49%	-10.02%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-47.12%	-18.64%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-53	-33	-90	-100	-165
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-53	-32	-91	-104	-173
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	8.17	6.96	6.72	4.64
Price to Tangible Book Value (P/TBV)	0.00	8.17	6.96	6.72	4.64
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.07	0.32	0.49	0.09
Long-Term Debt to Equity	0.00	0.07	0.32	0.49	0.09
Financial Leverage	-1.07	-1.08	-1.13	-1.12	-1.03
Leverage Ratio	1.09	1.15	1.47	1.72	1.22
Compound Leverage Factor	1.09	1.15	1.46	1.65	1.13
Debt to Total Capital	0.00%	6.61%	24.39%	32.91%	8.07%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	6.61%	24.39%	32.91%	8.07%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	277.88%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-177.88%	93.39%	75.58%	67.06%	91.93%
Debt to EBITDA	0.00	-0.15	-0.27	-0.48	-0.29
Net Debt to EBITDA	0.00	2.33	0.99	1.06	3.41
Long-Term Debt to EBITDA	0.00	-0.15	-0.27	-0.48	-0.29
Debt to NOPAT	0.00	-0.20	-0.39	-0.70	-0.43
Net Debt to NOPAT	0.00	3.14	1.41	1.55	5.04
Long-Term Debt to NOPAT	0.00	-0.20	-0.39	-0.70	-0.43
Altman Z-Score	2.21	21.81	2.28	2.23	19.79
Noncontrolling Interest Sharing Ratio	277.88%	116.49%	0.02%	0.04%	0.01%
Liquidity Ratios	-	-	-	-	-
Current Ratio	22.55	10.73	4.91	7.71	25.67
Quick Ratio	22.30	10.36	4.48	7.21	25.26
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-22	-57	-75	-113
Operating Cash Flow to CapEx	-82,878.57%	-474.16%	-109,025.81%	-146,319.05%	-13,855.86%
Free Cash Flow to Firm to Interest Expense	0.00	-1,076.57	-57.12	-19.88	-14.84
Operating Cash Flow to Interest Expense	-209.69	-1,185.40	-68.14	-24.35	-17.66
Operating Cash Flow Less CapEx to Interest Expense	-209.95	-1,435.40	-68.20	-24.36	-17.79
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	-3.48	-6.03	-13	-9.15	-13
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	-2.55	-6.97	3.84	-3.86
Enterprise Value (EV)	134	493	445	573	2,088
Market Capitalization	48	569	535	683	2,678
Book Value per Share	($279.24)	$3.27	$2.78	$2.29	$9.11
Tangible Book Value per Share	($279.24)	$3.27	$2.78	$2.29	$9.11
Total Capital	50	75	102	152	628
Total Debt	0.00	4.92	25	50	51
Total Long-Term Debt	0.00	4.92	25	50	51
Net Debt	-54	-76	-90	-111	-590
Capital Expenditures (CapEx)	0.04	5.00	0.06	0.06	0.97
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.85	-4.83	-15	-11	-15
Debt-free Net Working Capital (DFNWC)	52	75	100	150	626
Net Working Capital (NWC)	52	75	100	150	626
Net Nonoperating Expense (NNE)	17	8.53	25	25	35
Net Nonoperating Obligations (NNO)	-54	-76	-90	-111	-590
Total Depreciation and Amortization (D&A)	0.25	0.18	-0.85	-4.09	-8.06
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($2.43)	($3.35)	($2.25)	($2.75)
Adjusted Weighted Average Basic Shares Outstanding	0.00	27.05M	26.57M	42.71M	55.33M
Adjusted Diluted Earnings per Share	$0.00	($2.43)	($3.35)	($2.25)	($2.75)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	27.05M	26.57M	42.71M	55.33M
Adjusted Basic & Diluted Earnings per Share	$0.00	($2.43)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	13.44M	44.26M	54.45M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-34	-24	-64	-71	-117
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	-320.81	-1,630.15	-90.54	-26.46	-21.67
NOPAT to Interest Expense	-220.29	-1,204.07	-64.15	-18.86	-15.34
EBIT Less CapEx to Interest Expense	-321.06	-1,880.15	-90.60	-26.48	-21.79
NOPAT Less CapEx to Interest Expense	-220.55	-1,454.07	-64.21	-18.88	-15.47
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-8.48%	0.00%	0.00%	-0.01%

This table displays calculated financial ratios and metrics derived from Vera Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-234.14%	-98.39%	-84.43%	-38.93%	3.36%	16.82%	-2.58%	-68.84%	-130.03%	-80.38%
EBIT Growth	-229.56%	-94.47%	-81.36%	-43.36%	15.06%	18.86%	0.50%	-71.73%	-131.99%	-81.55%
NOPAT Growth	-248.10%	-102.48%	-83.64%	-45.91%	13.82%	19.51%	0.47%	-69.97%	-128.91%	-80.98%
Net Income Growth	-224.25%	-92.55%	-76.00%	-35.74%	18.54%	20.91%	5.61%	-67.19%	-131.95%	-69.27%
EPS Growth	-152.78%	-111.25%	-12.68%	16.36%	50.55%	54.24%	30.00%	-34.78%	-88.89%	-33.33%
Operating Cash Flow Growth	-235.89%	-228.70%	-192.75%	6.63%	-24.72%	-18.82%	-28.67%	-39.44%	-60.56%	-55.83%
Free Cash Flow Firm Growth	-381.49%	-82.57%	-536.00%	2.30%	49.59%	-37.60%	-87.10%	-531.91%	-309.46%	-33.50%
Invested Capital Growth	-111.05%	-115.62%	-20.23%	-168.55%	-190.38%	29.55%	99.62%	59.81%	-23.01%	-42.12%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-67.29%	-31.99%	6.02%	33.05%	-16.37%	-13.62%	-15.90%	-10.19%	-58.54%	10.91%
EBIT Q/Q Growth	-67.46%	-30.42%	5.85%	30.28%	0.78%	-24.57%	-15.46%	-20.34%	-34.03%	2.51%
NOPAT Q/Q Growth	-67.66%	-33.03%	6.92%	29.71%	0.97%	-24.23%	-15.11%	-20.03%	-33.36%	1.78%
Net Income Q/Q Growth	-66.16%	-31.44%	7.31%	32.95%	0.29%	-27.61%	-10.63%	-18.76%	-38.34%	6.88%
EPS Q/Q Growth	-65.45%	-29.67%	32.20%	42.50%	2.17%	-20.00%	-3.70%	-10.71%	-37.10%	15.29%
Operating Cash Flow Q/Q Growth	3.22%	-14.89%	-24.24%	32.41%	-29.27%	-9.45%	-34.55%	26.75%	-48.84%	-6.23%
Free Cash Flow Firm Q/Q Growth	-172.40%	-5.75%	-17.42%	71.11%	-40.54%	-188.66%	-59.66%	2.44%	8.93%	5.88%
Invested Capital Q/Q Growth	33.44%	-236.78%	-12.48%	-6.50%	28.02%	18.29%	99.39%	-11,069.64%	-120.32%	5.59%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	98.33%	99.10%	97.57%	93.83%	94.30%	96.60%	92.56%	91.35%	94.29%	90.06%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-76.85%	-121.58%	-69.86%	-81.94%	-89.59%	-107.50%	-36.89%	-46.05%	-65.11%	-44.83%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-76.85%	-121.55%	-69.85%	-81.94%	-89.59%	-107.45%	-36.89%	-46.05%	-65.10%	-44.82%
Return on Equity Simple (ROE_SIMPLE)	-69.49%	0.00%	-64.70%	-76.39%	-83.08%	0.00%	-26.67%	-32.89%	-46.49%	0.00%
Net Operating Profit after Tax (NOPAT)	-18	-24	-22	-15	-15	-19	-22	-26	-35	-34
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-7.12%	-10.79%	-5.14%	-3.38%	-3.99%	-6.71%	-2.51%	-3.09%	-5.38%	-2.62%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-12.48%	-	-	-	-5.45%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-25	-33	-31	-21	-21	-27	-31	-37	-49	-48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-25	-33	-31	-21	-24	-28	-32	-35	-56	-50
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.47	6.96	2.18	5.06	4.91	6.72	6.64	6.04	8.39	4.64
Price to Tangible Book Value (P/TBV)	5.47	6.96	2.18	5.06	4.91	6.72	6.64	6.04	8.39	4.64
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.05	0.32	0.16	0.18	0.20	0.49	0.14	0.15	0.17	0.09
Long-Term Debt to Equity	0.05	0.32	0.16	0.18	0.20	0.49	0.14	0.15	0.17	0.09
Financial Leverage	-1.03	-1.13	-1.09	-1.08	-1.07	-1.12	-1.03	-1.05	-1.06	-1.03
Leverage Ratio	1.16	1.47	1.28	1.31	1.34	1.72	1.23	1.26	1.32	1.22
Compound Leverage Factor	1.14	1.46	1.25	1.23	1.26	1.66	1.14	1.16	1.24	1.10
Debt to Total Capital	4.49%	24.39%	13.63%	15.08%	16.84%	32.91%	12.40%	13.29%	14.86%	8.07%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	4.49%	24.39%	13.63%	15.08%	16.84%	32.91%	12.40%	13.29%	14.86%	8.07%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	95.51%	75.58%	86.37%	84.92%	83.16%	67.06%	87.60%	86.71%	85.12%	91.93%
Debt to EBITDA	-0.07	-0.27	-0.24	-0.23	-0.23	-0.48	-0.48	-0.42	-0.34	-0.29
Net Debt to EBITDA	1.48	0.99	1.64	1.41	1.26	1.06	3.37	2.80	2.05	3.41
Long-Term Debt to EBITDA	-0.07	-0.27	-0.24	-0.23	-0.23	-0.48	-0.48	-0.42	-0.34	-0.29
Debt to NOPAT	-0.10	-0.39	-0.34	-0.32	-0.33	-0.70	-0.70	-0.61	-0.50	-0.43
Net Debt to NOPAT	2.12	1.41	2.34	1.99	1.78	1.55	4.96	4.07	2.98	5.04
Long-Term Debt to NOPAT	-0.10	-0.39	-0.34	-0.32	-0.33	-0.70	-0.70	-0.61	-0.50	-0.43
Altman Z-Score	11.97	3.71	2.90	6.55	5.37	3.61	21.19	16.63	17.36	20.38
Noncontrolling Interest Sharing Ratio	0.00%	0.02%	0.01%	0.00%	0.00%	0.04%	0.00%	0.00%	0.01%	0.01%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.85	4.91	8.69	7.10	6.97	7.71	28.63	21.43	13.76	25.67
Quick Ratio	7.19	4.48	8.38	6.75	6.50	7.21	27.76	20.87	13.35	25.26
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-16	-17	-19	-5.61	-7.88	-23	-36	-35	-32	-30
Operating Cash Flow to CapEx	-48,473.68%	0.00%	0.00%	0.00%	0.00%	-39,911.11%	0.00%	0.00%	-15,497.90%	-6,074.73%
Free Cash Flow to Firm to Interest Expense	-106.40	-27.61	-22.22	-6.14	-8.36	-21.57	-19.06	-18.54	-16.67	-16.23
Operating Cash Flow to Interest Expense	-125.31	-35.33	-30.08	-19.44	-24.36	-23.83	-17.75	-12.96	-19.05	-20.93
Operating Cash Flow Less CapEx to Interest Expense	-125.56	-35.33	-30.08	-19.44	-24.36	-23.89	-17.75	-12.96	-19.18	-21.28
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-3.86	-13	-15	-16	-11	-9.15	-0.06	-6.26	-14	-13
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-2.03	-6.97	-2.46	-9.77	-7.35	3.84	15	9.31	-2.58	-3.86
Enterprise Value (EV)	469	445	171	554	473	573	1,994	1,645	2,121	2,088
Market Capitalization	578	535	343	710	608	683	2,348	1,979	2,423	2,678
Book Value per Share	$3.90	$2.78	$3.56	$3.17	$2.79	$2.29	$6.49	$5.99	$5.27	$9.11
Tangible Book Value per Share	$3.90	$2.78	$3.56	$3.17	$2.79	$2.29	$6.49	$5.99	$5.27	$9.11
Total Capital	111	102	183	165	149	152	404	378	340	628
Total Debt	4.97	25	25	25	25	50	50	50	50	51
Total Long-Term Debt	4.97	25	25	25	25	50	50	50	50	51
Net Debt	-110	-90	-172	-156	-135	-111	-354	-334	-303	-590
Capital Expenditures (CapEx)	0.04	0.00	0.00	0.00	0.00	0.06	0.00	0.00	0.24	0.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.36	-15	-16	-17	-13	-11	-1.84	-8.06	-16	-15
Debt-free Net Working Capital (DFNWC)	109	100	181	164	147	150	402	376	338	626
Net Working Capital (NWC)	109	100	181	164	147	150	402	376	338	626
Net Nonoperating Expense (NNE)	7.01	8.93	8.19	4.78	4.87	6.74	6.60	7.57	12	9.19
Net Nonoperating Obligations (NNO)	-110	-90	-172	-156	-135	-111	-354	-334	-303	-590
Total Depreciation and Amortization (D&A)	-0.15	-0.60	-0.51	0.52	-3.08	-1.17	-1.47	1.50	-6.68	-1.79
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.91)	($1.18)	($0.80)	($0.46)	($0.45)	($0.54)	($0.56)	($0.62)	($0.85)	($0.72)
Adjusted Weighted Average Basic Shares Outstanding	27.22M	26.57M	37.67M	44.27M	44.36M	42.71M	50.97M	54.73M	54.90M	55.33M
Adjusted Diluted Earnings per Share	($0.91)	($1.18)	($0.80)	($0.46)	($0.45)	($0.54)	($0.56)	($0.62)	($0.85)	($0.72)
Adjusted Weighted Average Diluted Shares Outstanding	27.22M	26.57M	37.67M	44.27M	44.36M	42.71M	50.97M	54.73M	54.90M	55.33M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	27.66M	44.26M	44.26M	44.32M	44.43M	54.45M	54.70M	54.83M	63.32M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-18	-24	-22	-15	-15	-19	-22	-26	-35	-34
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-170.74	-54.65	-35.26	-23.51	-22.61	-25.17	-16.09	-19.30	-25.55	-25.76
NOPAT to Interest Expense	-120.21	-39.24	-25.04	-16.83	-16.15	-17.93	-11.43	-13.67	-18.01	-18.29
EBIT Less CapEx to Interest Expense	-171.00	-54.65	-35.26	-23.51	-22.61	-25.23	-16.09	-19.30	-25.67	-26.10
NOPAT Less CapEx to Interest Expense	-120.47	-39.24	-25.04	-16.83	-16.15	-17.99	-11.43	-13.67	-18.13	-18.64
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.01%

Frequently Asked Questions About Vera Therapeutics' Financials

When does Vera Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Vera Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Vera Therapeutics' net income changed over the last 4 years?

Vera Therapeutics' net income appears to be on an upward trend, with a most recent value of -$152.15 million in 2024, rising from -$53.41 million in 2020. The previous period was -$95.99 million in 2023.

What is Vera Therapeutics's operating income?

Vera Therapeutics's total operating income in 2024 was -$167.17 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $167.17 million

How has Vera Therapeutics revenue changed over the last 4 years?

Over the last 4 years, Vera Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does Vera Therapeutics have?

Vera Therapeutics' total liabilities were at $78.53 million at the end of 2024, a 6.3% increase from 2023, and a 1,715.2% increase since 2020.

How much cash does Vera Therapeutics have?

In the past 4 years, Vera Therapeutics' cash and equivalents has ranged from $43.46 million in 2022 to $92.65 million in 2024, and is currently $92.65 million as of their latest financial filing in 2024.

How has Vera Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, Vera Therapeutics' book value per share changed from -279.24 in 2020 to 9.11 in 2024, a change of -103.3%.

Related Companies

This page (NASDAQ:VERA) was last updated on 4/19/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vera Therapeutics (VERA) Financials

Frequently Asked Questions About Vera Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vera Therapeutics (VERA) Financials

Annual Income Statements for Vera Therapeutics

Quarterly Income Statements for Vera Therapeutics

Annual Cash Flow Statements for Vera Therapeutics

Quarterly Cash Flow Statements for Vera Therapeutics

Annual Balance Sheets for Vera Therapeutics

Quarterly Balance Sheets for Vera Therapeutics

Annual Metrics and Ratios for Vera Therapeutics

Quarterly Metrics and Ratios for Vera Therapeutics

Frequently Asked Questions About Vera Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools